Global Ophthalmic Drugs Market to reach USD 38.8 billion by 2026

Global Ophthalmic Drugs Market Size Study, by Disease Type (Dry Eye Drugs, Retinal Disorders Drugs, Ophthalmic Anti-Allergy/Inflammatory/Infective Drugs, Anti-glaucoma Drugs), by Delivery Type (Capsules & Tablets, Gels, Eye drops, Eye Ointment, Eye Solutions), by Product Type (Prescription Drugs and Over-the-Counter Drugs), and Regional Forecasts, 2019-2026 (USD Billion/Million)
Product Code:  HALDAT_67833206
Chapter 1.	Executive Summary 
1.1.	Market Snapshot
1.2.	Key Trends
1.3.	Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
1.3.1.	Ophthalmic Drugs Market, by Disease Type, 2016-2026 (USD Billion)
1.3.2.	Ophthalmic Drugs Market, by Delivery Type, 2016-2026 (USD Billion)
1.3.3.	Ophthalmic Drugs Market, by Product Type, 2016-2026 (USD Billion)
1.3.4.	Ophthalmic Drugs Market, by Region, 2016-2026 (USD Billion)
1.4.	Estimation Methodology
1.5.	Research Assumption
Chapter 2.	Global Ophthalmic Drugs Market Definition and Scope 
2.1.	Objective of the Study
2.2.	Market Definition & Scope
2.2.1.	Industry Evolution
2.2.2.	Scope of the Study
2.3.	Years Considered for the Study
2.4.	Currency Conversion Rates
Chapter 3.	Global Ophthalmic Drugs Market Dynamics	
3.1.	See Saw Analysis
3.1.1.	Market Drivers
3.1.2.	Market Challenges
3.1.3.	Market Opportunities
Chapter 4.	Global Ophthalmic Drugs Market Industry Analysis
4.1.	Porter’s 5 Force Model
4.1.1.	Bargaining Power of Buyers
4.1.2.	Bargaining Power of Suppliers
4.1.3.	Threat of New Entrants
4.1.4.	Threat of Substitutes
4.1.5.	Competitive Rivalry
4.1.6.	Futuristic Approach to Porter’s 5 Force Model
4.2.	PEST Analysis
4.2.1.	Political Scenario
4.2.2.	Economic Scenario
4.2.3.	Social Scenario
4.2.4.	Technological Scenario
4.3.	Key Buying Criteria (On Demand)
4.4.	Regulatory Framework (On Demand)
4.5.	Investment Vs Adoption Scenario (On Demand)
4.6.	Analyst Recommendation & Conclusion
Chapter 5.	Global Ophthalmic Drugs Market, by Disease Type 
5.1.	Market Snapshot 
5.2.	Market Performance - Potential Model
5.3.	Ophthalmic Drugs Market, Sub Segment Analysis
5.3.1.	 Dry Eye Drugs
5.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.3.2.	  Retinal Disorder Drugs
5.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.3.3.	   Ophthalmic Anti-Allergy/Inflammatory/Infective Drugs
5.3.3.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.3.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.3.4.	 Anti-Glaucoma Drugs
5.3.4.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
5.3.4.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
Chapter 6.	Global Ophthalmic Drugs Market, by Delivery Type          
6.1.	Market Snapshot 
6.2.	Market Performance - Potential Model
6.3.	Ophthalmic Drugs Market, Sub Segment Analysis
6.3.1.	  Capsules & Tablets
6.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.3.2.	  Gels
6.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.3.3.	  Eye Drops
6.3.3.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.3.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.3.4.	Eye Ointments
6.3.4.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.4.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.3.5.	  Eye Solutions 
6.3.5.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
6.3.5.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
Chapter 7.	Global Ophthalmic Drugs Market, by  Product type          
7.1.	Market Snapshot 
7.2.	Market Performance - Potential Model
7.3.	Ophthalmic Drugs Market, Sub Segment Analysis
7.3.1.	   Prescription Drugs
7.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
7.3.1.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.3.2.	   Over-the-Counter Drugs
7.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
7.3.2.2.	Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 8.	Global Ophthalmic Drugs Market, by Regional Analysis
8.1.	Ophthalmic Drugs Market, Regional Market Snapshot (2016-2026)
8.2.	North America Ophthalmic Drugs Market Snapshot
8.2.1.	U.S.
8.2.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.2.1.2.	 Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.2.1.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.2.1.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.2.2.	Canada
8.2.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.2.2.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.2.2.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.2.2.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.	Europe Ophthalmic Drugs Market Snapshot
8.3.1.	U.K. 
8.3.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.3.1.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.3.2.	Rest of Europe
8.3.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.3.2.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.4.	Asia Ophthalmic Drugs Market Snapshot
8.4.1.	China 
8.4.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.1.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.4.1.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.1.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.4.2.	India 
8.4.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.4.2.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.4.3.	Japan
8.4.3.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.4.3.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.4.4.	Rest of Asia Pacific
8.4.4.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.4.4.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.5.	Latin America Ophthalmic Drugs Market Snapshot
8.5.1.	Brazil 
8.5.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.5.1.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.5.1.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.1.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   

8.5.2.	Mexico 
8.5.2.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.5.2.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.5.2.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.2.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
8.6.	Rest of The World 
8.6.1.	Middle East and Africa
8.6.1.1.	Market estimates & forecasts, 2016-2026 (USD Billion)
8.6.1.2.	Disease Type breakdown estimates & forecasts, 2016-2026 (USD Billion) 
8.6.1.3.	 Delivery Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.1.4.	Product Type breakdown estimates & forecasts, 2016-2026 (USD Billion)   
Chapter 9.	Competitive Intelligence
9.1.	Company Market Share (Subject to Data Availability)
9.2.	Top Market Strategies
9.3.	Company Profiles
9.3.1.	  Valeant Pharmaceuticals International Inc.
9.3.1.1.	Overview
9.3.1.2.	Financial (Subject to Data Availability)
9.3.1.3.	Product Summary
9.3.1.4.	Recent Developments
9.3.2.	   Sun Pharmaceutical Industries Ltd.
9.3.3.	Shire Plc 
9.3.4.	Regeneron Pharmaceuticals, Inc.
9.3.5.	Alcon 
9.3.6.	Pfizer Inc.
9.3.7.	Genentech, Inc.
9.3.8.	Santen Pharmaceutical Co., Ltd 
9.3.9.	Merck & Co., Inc. 
9.3.10.	Allergan, Plc
Chapter 10.	Research Process
10.1.	Research Process
10.1.1.	Data Mining
10.1.2.	Analysis
10.1.3.	Market Estimation
10.1.4.	Validation
10.1.5.	Publishing
10.1.6.	Research Assumption

Global Ophthalmic Drugs Market industry valued approximately USD 25.7 billion in 2018 is anticipated to grow with a healthy growth rate of more than 5.27% over the forecast period 2019-2026. Rising frequencies of eye disorders like macular degeneration, presbyopia, and diabetic retinopathy among the most prevalent age groups are speculated to propel the growth. For instance, As per WHO, about 253 million people are living with vision impairment of which 36 million are blind and 217 million people suffer moderate to severe vision impairment. However, as per WHO about 80% of all vision impairment can be prevented or cured. Thus, these factors are expected to boost the demand of ophthalmic drugs for the eye treatment hence contributing towards market growth during the forecast period. Further, as per the International Agency for the Prevention of blindness, nearly about 1.1 billion people are with near vision impairment and about 89% of visually impaired people are living in low and middle-income countries and about 55% of visually impaired people are women. Thus, rise in the eye related diseases is expected to fuel the demand for the ophthalmic drug. This is expected to boost the market of global ophthalmic drugs market.

The regional analysis of global ophthalmic drugs market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to increasing prevalence of glaucomo coupled with the well-established healthcare infrastructure. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such as rising incidences of glaucoma and tear substitutes coupled with improving healthcare infrastructure would create lucrative growth prospects for the ophthalmic drugs market across Asia-Pacific region.

Major market player included in this report are:
Valeant Pharmaceuticals International, Inc.
Sun Pharmaceutical Industries Ltd
Shire Plc
Regeneron Pharmaceuticals, Inc.
Alcon
Pfizer Inc.
Genentech, Inc.
Santen Pharmaceutical Co., Ltd.

The objective of the study is to define market sizes of different segments & countries in previous years and to forecast the values to the next eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers & restraining factors which will define the future growth of the market. Additionally, it will also incorporate the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disease Type:
Dry Eye Drugs
Retinal Disorders Drugs
Ophthalmic Anti-Allergy/Inflammatory/Infective Drugs
Anti-Glaucoma Drugs

By Delivery Type:
Capsules & Tablets
Gels
Eye Drops
Eye Ointment
Eye Solutions

By Product Type:
Prescription Drugs
Over-the-Counter Drugs

By Regions:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, the years considered for the study are as follows:

Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026

Target Audience of the Ophthalmic Drugs Market Study

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.



Loading…